Login / Signup

Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer.

Tereza LanickovaMichal HenslerLenka KasikovaSarka VosahlikovaArtemis AngelidouJosef PasulkaHannah GrieblerJana DrozenováKaterina MojzisovaAnn VankerckhovenJan LacoAleš RyškaPavel DundrRoman KocianDavid CibulaTomas BrtnickyPetr SkapaFrancis JacobMarek KovářIvan PraznovecIain A McNeishMichael Jiří HalaškaLukáš RobAn CoosemansSandra OrsulicLorenzo GalluzziRadek SpisekJitka Fucikova
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Altogether, our findings suggest that NACT promotes TLS formation and maturation in HGSOC lesions, de facto preserving an intratumoral ICI-sensitive T-cell phenotype. These observations emphasize the role of rational design, especially relative to the administration schedule, for clinical trials testing chemotherapy plus ICIs in patients with HGSOC.
Keyphrases
  • clinical trial
  • locally advanced
  • squamous cell carcinoma
  • small cell lung cancer
  • cancer therapy
  • randomized controlled trial
  • rectal cancer
  • phase ii
  • drug delivery
  • mass spectrometry
  • open label
  • phase iii
  • double blind